SCHEMBL32687673

SCHEMBL32687673

COc1ccc(CNCC2(NC(=O)OC(C)(C)C)CCC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ANPEP P15144 1/20 0.43
ERAP2 Q6P179 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
P2RX7 Q99572 1/20 0.42
DPP7 Q9UHL4 2/20 0.41
PPIA P62937 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
EPHX2 P34913 1/20 0.41
NR1H4 Q96RI1 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
ATM Q13315 1/20 0.41
CACNA1B Q00975 2/20 0.41
LMNA P02545 2/20 0.41
MAPT P10636 1/20 0.41
ALDH1A1 P00352 2/20 0.40
HDAC3 O15379 1/20 0.40
HDAC1 Q13547 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5115679 0.82 APLNR (0.49) P2RX7DPP7MEN1KMT2AALDH1A1
SCHEMBL26388320 0.76 PPIA (0.43) SMN1; SMN2NPC1RAB9APPIAMEN1
SCHEMBL32687883 0.75 CACNA1B (0.45) SMN1; SMN2P2RX7PPIACACNA1BLMNA
SCHEMBL32687398 0.75 CACNA1B (0.45) SMN1; SMN2P2RX7PPIACACNA1BLMNA
SCHEMBL7652554 0.75 NPC1 (0.58) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL21066545 0.75 KMT2A (0.52) ANPEPERAP2SMN1; SMN2NPC1RAB9A
SCHEMBL3662863 0.74 SMN1; SMN2 (0.50) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL26388338 0.74 PPARG (0.42) SMN1; SMN2NPC1RAB9APPIAMEN1
SCHEMBL30699647 0.74 DPP7 (0.51) SMN1; SMN2NPC1RAB9ADPP7MEN1
SCHEMBL12493302 0.74 MAPT (0.55) SMN1; SMN2MEN1KMT2AEPHX2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078134-A1 Macrocyclic Compounds as RAS Inhibitors BEONE MEDICINES I GMBH (CH) 2026-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260078134-A1 Macrocyclic Compounds as RAS Inhibitors NRAS, KRAS, HRAS ANPEP 3027/4885ERAP2 4554/4885SMN1; SMN2 1533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.